EscharEx is an enzyme commercialized by MediWound, with a leading Phase II program in Diabetic Foot Ulcers;Venous Leg Ulcers (Crural Ulcer). According to Globaldata, it is involved in 4 clinical trials, of which 3 were completed, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of EscharEx’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData


Data Insights Net Present Value Model: MediWound Ltd's EscharEx

Buy the Model

Data Insights

The gold standard of business intelligence.

Find out more

The revenue for EscharEx is expected to reach an annual total of $6 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

EscharEx Overview

EscharEx is under development for the debridement of chronic and other hard to heal venous leg ulcers, diabetic foot ulcers (lower extremity), traumatic/post operative wounds. It is applied topically. The drug candidate is a proteolytic enzyme. The development of the drug candidate is based on proteolytic enzymatic technology.

MediWound Overview

MediWound is a biopharmaceutical company that develops, manufactures and markets novel therapeutics to address the unmet needs in the areas of chronic, severe burns, other hard-to-heal wounds and for connective tissue disorders. The company uses its patented proteolytic enzyme technology for the development of its products. The company offers NexoBrid, a drug for the removal of damaged or dead tissue, namely, eschar, in adults with severe burns (deep partial and full-thickness thermal burns). EscharEX, pipeline drug candidate for the removal of damaged, dead or infected tissues from chronic wounds; MWPC003, a pre-clinical candidate for treating connective tissue Disorders. The company markets NexoBrid in Europe and Israel through its own commercial organization and in Russia, Peru, India, Bangladesh, South Korea, Argentina through distributors. MediWound is headquartered in Yavne, Israel.
The company reported revenues of (US Dollars) US$18.7 million for the fiscal year ended December 2023 (FY2023), a decrease of 29.5% over FY2022. The operating loss of the company was US$15.3 million in FY2023, compared to an operating loss of US$8.4 million in FY2022. The net loss of the company was US$6.7 million in FY2023, compared to a net loss of US$19.6 million in FY2022.

For a complete picture of EscharEx’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.